Scarica l'app Stockscreener
50.80
0.95%
0.48
Dopo l'orario di chiusura:
50.75
-0.05
-0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$50.32
Aprire:
$50.49
Volume 24 ore:
5.10M
Relative Volume:
1.10
Capitalizzazione di mercato:
$102.47B
Reddito:
$42.06B
Utile/perdita netta:
$7.96B
Rapporto P/E:
14.49
EPS:
3.5062
Flusso di cassa netto:
$5.64B
1 W Prestazione:
+6.61%
1M Prestazione:
+3.50%
6M Prestazione:
+33.79%
1 anno Prestazione:
+43.10%
Intervallo 1D:
$50.49
$51.37
Intervallo di 1 settimana:
$47.77
$51.37
Portata 52W:
$32.38
$51.46
Gsk Plc Adr Stock (GSK) Company Profile
Nome
Gsk Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GSK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
50.80 | 101.50B | 42.06B | 7.96B | 5.64B | 3.5062 |
|
LLY
Lilly Eli Co
|
1,039.51 | 951.18B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
224.44 | 533.63B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.93 | 390.19B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
152.22 | 286.13B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.89 | 284.29B | 46.69B | 15.29B | 9.25B | 3.4329 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2026-01-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Downgrade | Berenberg | Buy → Hold |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-07-08 | Downgrade | UBS | Buy → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-03-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2024-01-03 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-03-17 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Ripresa | Goldman | Buy |
| 2023-01-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Downgrade | UBS | Neutral → Sell |
| 2022-09-15 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Ripresa | Citigroup | Neutral |
| 2022-02-11 | Downgrade | DZ Bank | Buy → Hold |
| 2021-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Hold |
| 2020-11-02 | Aggiornamento | Liberum | Hold → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-02-12 | Downgrade | Shore Capital | Hold → Sell |
| 2020-01-16 | Downgrade | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Iniziato | SVB Leerink | Outperform |
| 2019-11-21 | Aggiornamento | UBS | Neutral → Buy |
| 2019-10-11 | Aggiornamento | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Ripresa | Citigroup | Neutral |
| 2019-09-03 | Aggiornamento | Societe Generale | Sell → Buy |
| 2019-08-13 | Ripresa | JP Morgan | Neutral |
| 2019-06-17 | Ripresa | Morgan Stanley | Underweight |
| 2019-03-08 | Downgrade | Shore Capital | Buy → Hold |
| 2019-02-22 | Downgrade | UBS | Buy → Neutral |
| 2019-01-14 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-08-30 | Downgrade | Liberum | Buy → Hold |
| 2018-04-04 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Aggiornamento | Kepler | Reduce → Hold |
Mostra tutto
Gsk Plc Adr Borsa (GSK) Ultime notizie
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Oncolytic Virotherapy Market - GlobeNewswire Inc.
GSK plc (ADR): Defensive pharma heavyweight tests investors’ patience as Wall Street edges cautiou - AD HOC NEWS
Price Over Earnings Overview: GSK - Sahm
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
GSK plc (ADR): Defensive Pharma Giant Tests Investors’ Patience As Shares Slip Despite Solid Pipel - AD HOC NEWS
Looking Into GSK PLC's Recent Short Interest - Sahm
Jefferies Reaffirms a Buy Rating on GSK plc (GSK)Here's Why - Finviz
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - TradingView — Track All Markets
GSK (NYSE:GSK) Lowered to “Underweight” Rating by Barclays - Defense World
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK - Sahm
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
The Truth About GSK plc (ADR): Viral Hype Or Sneaky Safe Bet For Your Portfolio? - AD HOC NEWS
GSK plc (ADR): Defensive Giant Or Underestimated Comeback Story? - AD HOC NEWS
The Truth About GSK plc (ADR): Is Wall Street Sleeping on This Pharma Beast? - AD HOC NEWS
GSK plc (ADR): Defensive Pharma Heavyweight Tests Investor Patience As Street Turns Selectively Bull - AD HOC NEWS
The Truth About GSK plc (ADR): Is This ‘Boring’ Stock Quietly Becoming a Power Play? - AD HOC NEWS
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast? - AD HOC NEWS
New Report Calls Achieve Life's Cytisinicline Best Therapy To Quit Smoking - Sahm
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
The Market Is All In on the Magnificent Seven. Where Should Investors Look Next? - Morningstar
HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target - Finviz
Why is GSK plc (GSK) One of the Best Affordable Healthcare Stocks to Buy Now? - Finviz
Bard Financial Services Inc. Purchases 23,400 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Price History & Data - Traders Union
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Brokerages - Defense World
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK - Sahm
Douglas Lane & Associates LLC Sells 196,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Sahm
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc - ts2.tech
FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year - Sahm
GSK (NYSE:GSK) Major Shareholder Plc Gsk Purchases 1,470,000 Shares - Defense World
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms - ts2.tech
GSK (NYSE:GSK) Major Shareholder Purchases 1,470,000 Shares - MarketBeat
Gsk Plc Adr Azioni (GSK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):